Koschmann, Carl, Al-Holou, Wajd N., Clausen, Madison, Dang, Derek, Doherty, Robert, Duchatel, Ryan, Dun, Matthew, Filbin, Mariella, Franson, Andrea, Galban, Stefanie, Garcia Moure, Marc, Garton, Hugh, Alonso, Marta M., Gowda, Pruthvi, Marques, JG, Hawkins, C, Heath, A, Hulleman, E, Ji, S, Jones, C, Kilburn, L, Kline, C, Koldobskiy, MA, Anastas, Jamie, Lim, D, Lowenstein, PR, Lu, QR, Lum, J, Mack, S, Magge, S, Marini, B, Martin, D, Marupudi, N, Messinger, D, Bandopadhayay, Pratiti, Mody, R, Morgan, M, Mota, M, Muraszko, K, Mueller, S, Natarajan, SK, Nazarian, J, Niculcea, M, Nuechterlein, N, Okada, H, Barron, Tara, Opipari, V, Pai, MP, Pal, S, Peterson, E, Phoenix, T, Prensner, JR, Pun, M, Raju, GP, Reitman, ZJ, Resnick, A, Becher, Oren, Rogawski, D, Saratsis, A, Sbergio, SG, Souweidane, M, Stafford, JM, Tzaridis, T, Venkataraman, S, Vittorio, O, Wadden, J, Wahl, D, Cartaxo, Rodrigo, Wechsler-Reya, RJ, Yadav, VN, Zhang, X, Zhang, Q, Venneti, S, Castro, Maria G., Chung, Chan. Cell Press; 2024. A road map for the treatment of pediatric diffuse midline glioma.

Messinger, Dana, Harris, Micah K., Qin, Tingting, Mullan, Brendan, Siada, Ruby, Ravindran, Ramya, Niculcea, Michael, Dowling, Abigail R., Bradin, Joshua, Ginn, Kevin F., Gener, Melissa A. H., Dorris, Kathleen, Cummings, Jessica R., Vitanza, Nicholas A., Schmidt, SV, Spitzer, J, Li, J, Filbin, MG, Cao, X, Castro, MG, Lowenstein, PR, Mody, R, Chinnaiyan, A, Thomas, Chase, Desprez, PY, McAllister, S, Dun, Matthew D., Hawkins, C, Waszak, SM, Venneti, S, Koschmann, C, Yadav, VN, Yang, Tao, Sweha, Stefan R., Woo, Rinette, Siddaway, Robert, Burkert, Martin, Stallard, Stefanie. Oxford University Press; 2023. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.

Venneti, Sriram, Kawakibi, Abed Rahman, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y., Arrillaga-Romany, Isabel, Batchelor, Tracy T., Butowski, Nicholas A., Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A., de Groot, John, Ji, Sunjong, Mehta, M, Hall, MD, Daghistani, D, Cloughesy, TF, Ellingson, BM, Beccaria, K, Varlet, P, Kim, MM, Umemura, Y, Garton, H, Waszak, Sebastian M., Franson, A, Schwartz, J, Jain, R, Kachman, M, Baum, H, Burant, CF, Mottl, SL, Cartaxo, RT, John, V, Messinger, D, Sweha, StefanR, Qin, T, Peterson, E, Sajjakulnukit, P, Ravi, K, Waugh, A, Walling, D, Ding, Y, Xia, Z, Schwendeman, A, Hawes, D, Mota, Mateus, Yang, F, Judkins, AR, Wahl, D, Lyssiotis, CA, de la Nava, D, Alonso, MM, Eze, A, Spitzer, J, Schmidt, SV, Duchatel, Ryan J., Pun, Matthew, Dun, Matthew D., Cain, JE, Jiang, L, Stopka, SA, Baquer, G, Regan, MS, Filbin, MG, Agar, NYR, Zhao, L, Kumar-Sinha, C, Deogharkar, Akash, Mody, R, Chinnaiyan, A, Kurokawa, R, Pratt, D, Yadav, VN, Grill, J, Kline, C, Mueller, S, Resnick, A, Nazarian, J, Chung, Chan, Allen, JE, Odia, Y, Gardner, SL, Koschmann, C, Tarapore, Rohinton S.. American Association for Cancer Research; 2023. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways.